News blog

New drug pathways under investigation for ALS

A diagnosis of amyotrophic lateral sclerosis (ALS) is considered a life sentence. Most people with the neurodegenerative disease, which attacks the neurons responsible for motor control, only survive two or three years after their diagnosis — and 5,000 such diagnoses are made each year in the United States alone. Despite the need, however, there is only a single drug on the market that targets ALS: Rilutek (riluzole), made by France’s Sanofi. But this agent only prolongs life by two or three months on average. Recent advances provide some hope for future drug pathways that can be targeted to treat the disease.


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.